Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82.1M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
23.3M
-
Shares change
-
+5.48M
-
Total reported value, excl. options
-
$460M
-
Value change
-
+$113M
-
Number of buys
-
35
-
Number of sells
-
-9
-
Price
-
$19.77
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q4 2021
60 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q4 2021.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.3M shares
of 82.1M outstanding shares and own 28.35% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.88M shares), VR Adviser, LLC (1.85M shares), FRAZIER MANAGEMENT LLC (1.51M shares), PERCEPTIVE ADVISORS LLC (1.42M shares), Deep Track Capital, LP (1.34M shares), TCG Crossover Management, LLC (1.31M shares), Vivo Capital, LLC (1.3M shares), Avidity Partners Management LP (1.28M shares), Paradigm Biocapital Advisors LP (1.21M shares), and Fairmount Funds Management LLC (944K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.